Showing posts with label MELD. Show all posts
Showing posts with label MELD. Show all posts

February 25, 2014

Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and MELD score

Journal of Viral Hepatitis

Early View (Online Version of Record published before inclusion in an issue)

V. Virlogeux1,2,3,4, P. Pradat1,2,3, F. Bailly1,2,3, G. Funingana1, F. Gonçalves1, M. Maynard1, K. Hartig-Lavie1, M. Amiri1, F. Zoulim1,2,3,5,*

Article first published online: 25 FEB 2014

DOI: 10.1111/jvh.12237

© 2014 John Wiley & Sons Ltd

Keywords: glomerular filtration rate;  hepatitis C virus;  pegylated interferon;  protease inhibitor;  renal function;  ribavirin; triple therapy; virological response

Abstract

Summary

Triple therapy using telaprevir or boceprevir [hepatitis C virus (HCV)-NS3/NS4A protease inhibitors (PI)] in association with PEG-IFN/ribavirin has recently become the new standard of care (SOC) for treatment of HCV genotype 1 patients. Our objective was to assess the efficacy and tolerance of triple therapy in routine clinical practice. A total of 186 consecutive HCV patients initiating triple therapy were enrolled in a single centre study. Clinical, biological and virological data were collected at baseline and during follow-up as well as tolerance and side effect details. Among 186 HCV patients initiating triple therapy, 69% received telaprevir and 31% boceprevir. Sixty-one per cent of patients had cirrhosis. The overall extended rapid virological response (eRVR) rate and sustained virological response (SVR) rate were 57.0% and 59.7%, respectively. IL28B CC phenotype was associated with increased probability of achieving eRVR and SVR, whereas previous non-response was associated with low eRVR and SVR rates. The SVR rate increased from 30.8% in previously non-responders to 59.1% in partial non-responders and 75% in relapsers. SVR rate in naive patients was 62.5%. Glomerular filtration rate assessed by MDRD after 12 weeks of therapy was significantly reduced for both PI (P < 0.001). The model for end-stage liver disease(MELD) score was significantly increased at W12 for telaprevir (P = 0.008) and at W24 for boceprevir (P = 0.027). PI-based triple therapy leads to high rates of virological response even in previously non-responder patients. Renal function after triple therapy is impaired as well as MELD score in all patients. Cautious clinical monitoring should focus not only on haematological and dermatological side effects but also on renal function.

Source

February 2, 2014

A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding

Gastroenterology. 2014 Feb;146(2):412-419.e3. doi: 10.1053/j.gastro.2013.10.018. Epub 2013 Oct 19.

Reverter E1, Tandon P2, Augustin S3, Turon F4, Casu S4, Bastiampillai R2, Keough A2, Llop E4, González A3, Seijo S4, Berzigotti A4, Ma M2, Genescà J5, Bosch J1, García-Pagán JC1, Abraldes JG6.

Abstract

BACKGROUND & AIMS: Patients with cirrhosis with acute variceal bleeding (AVB) have high mortality rates (15%-20%). Previously described models are seldom used to determine prognoses of these patients, partially because they have not been validated externally and because they include subjective variables, such as bleeding during endoscopy and Child-Pugh score, which are evaluated inconsistently. We aimed to improve determination of risk for patients with AVB.

METHODS: We analyzed data collected from 178 patients with cirrhosis (Child-Pugh scores of A, B, and C: 15%, 57%, and 28%, respectively) and esophageal AVB who received standard therapy from 2007 through 2010. We tested the performance (discrimination and calibration) of previously described models, including the model for end-stage liver disease (MELD), and developed a new MELD calibration to predict the mortality of patients within 6 weeks of presentation with AVB. MELD-based predictions were validated in cohorts of patients from Canada (n = 240) and Spain (n = 221).

RESULTS: Among study subjects, the 6-week mortality rate was 16%. MELD was the best model in terms of discrimination; it was recalibrated to predict the 6-week mortality rate with logistic regression (logit, -5.312 + 0.207 • MELD; bootstrapped R(2), 0.3295). MELD values of 19 or greater predicted 20% or greater mortality, whereas MELD scores less than 11 predicted less than 5% mortality. The model performed well for patients from Canada at all risk levels. In the Spanish validation set, in which all patients were treated with banding ligation, MELD predictions were accurate up to the 20% risk threshold.

CONCLUSIONS: We developed a MELD-based model that accurately predicts mortality among patients with AVB, based on objective variables available at admission. This model could be useful to evaluate the efficacy of new therapies and stratify patients in randomized trials.

Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

KEYWORDS: AUROC, AVB, Cirrhosis, HCC, HVPG, Logistic Regression, MELD, Prognostic Model, ROC, TIPS, acute variceal bleeding, area under receiver operating characteristic curve, hepatic venous pressure gradient, hepatocellular carcinoma, model for end-stage liver disease, receiver operating characteristic, transjugular intrahepatic portosystemic shunt

PMID: 24148622 [PubMed - in process]

Source

December 22, 2013

Increased Long-Term Survival Among Patients with Hepatocellular Carcinoma After Implementation of Model for End-Stage Liver Disease Score

Clinical Gastroenterology and Hepatology

Article in Press

Robert J. Wong, Pardha Devaki, Long Nguyen, Ramsey Cheung, Cheryl Cho-Phan, Mindie H. Nguyen

Received 29 July 2013; received in revised form 14 November 2013; accepted 6 December 2013. published online 19 December 2013.
Accepted Manuscript

Abstract

Background & Aims

Assignment of model for end-stage liver disease (MELD) exception points to patients with hepatocellular carcinoma (HCC) who fall within Milan criteria, which began in 2003, increases their priority on liver transplantation waitlists. However, little is known about how this change affected survival of all patients with HCC (transplant eligible and ineligible). We compared long-term survival of HCC patients before and after this change.

Methods

We performed a large population-based cohort study using the Surveillance, Epidemiology, and End Results cancer registry to investigate survival times of patients with HCC before those who met the Milan criteria were given MELD exception points (1998–2003) and afterward (2004–2010), using Kaplan Meier methods. Multivariate Cox proportional hazards models evaluated independent predictors of survival.

Results

During 2004–2010, a significantly higher percentage of patients with HCC survived for 5 years compared to 1998-2003 (21.9% vs 13.0%, P<.001). This difference remained significant among all treatment groups (no therapy: 15.2% vs 10.2%, P<0.001; local tumor destruction: 37.6% vs 22.1%, P<0.001; resection: 55.5% vs 39.2%, P<0.001; transplantation: 77.2% vs 73.1%, P =0.12). Multivariate Cox proportional hazards models, inclusive of sex, age, ethnicity, Milan criteria, number and stage of tumor, and time period, showed increased survival of patients during 2004–2010 (hazard ratio [HR], 0.87; 95% confidence interval, 0.83–0.91; P<.001). Compared to non-Hispanic whites, Asians (HR, 0.81; 95% CI, 0.77–0.86; P<.001) and Hispanics (HR, 0.89, 95% CI, 0.84–0.95; P<.001) had longer survival times, whereas blacks had a trend toward shorter survival times (HR, 1.05; 95% CI 0.98–1.13; P=.16).

Conclusions

Patients with HCC who met Milan criteria had significantly longer survival times after implementation of the MELD exception points, regardless of sex or ethnicity. Blacks continued to have the lowest rates of 5 year survival.

Keywords: SEER, racial disparities, liver cancer, resource allocation

Abbreviations: CI, confidence interval, HCC, hepatocellular carcinoma, HR, hazard ratio, MELD, model for end stage liver disease, SEER,surveillance, epidemiology, and end results, TACE, transarterial chemoembolization, UNOS, United Network for Organ Sharing

Source

December 20, 2013

Predicting Survival after Liver Transplantation Based on Pre-Transplant MELD Score: a Systematic Review of the Literature

PLOS One

RESEARCH ARTICLE

Kristin B. Klein, Taenia D. Stafinski, Devidas Menon

Published: December 12, 2013 DOI: 10.1371/journal.pone.0080661

Abstract

The model for end-stage liver disease (MELD) score is used to stratify candidates for liver transplantation based on objective measures of disease severity. MELD has been validated as a predictor of wait-list mortality in transplantation candidates and has been postulated as a predictor of post-transplant survival. The purpose of this study was to examine the predictive value of the pre-transplantation MELD score on post-transplant survival from relevant existing studies. A systematic review and critical appraisal was performed using Cochrane guidelines. PubMed, the Cochrane Library, Embase, and Web of Science were searched for articles published in the English language since 2005 using a structured search strategy. There were 3058 discrete citations identified and screened for possible inclusion. Any study examining the relationship between pre-transplant MELD and post-transplant survival in the general transplant population was included. Thirty-seven studies met these criteria and were included in the review. Studies were all case series that typically involved stratified analyses of survival by MELD. They represented 15 countries and a total of 53,691 patients. There was significant clinical heterogeneity in patient populations across studies, which precluded performance of a meta-analysis. In 15 studies, no statistically significant association between MELD and post-transplant survival was found. In the remaining 22, some association was found. Eleven studies also measured predictive ability with c-statistics. Values were below 0.7 in all but two studies, suggesting poor predictive value. In summary, while the majority of studies reported an association between pre-transplantation MELD score and post-transplant survival, they represented a low level of evidence. Therefore, their findings should be interpreted conservatively.

Citation: Klein KB, Stafinski TD, Menon D (2013) Predicting Survival after Liver Transplantation Based on Pre-Transplant MELD Score: a Systematic Review of the Literature. PLoS ONE 8(12): e80661. doi:10.1371/journal.pone.0080661

Editor: Evren Alici, Karolinska Institutet, Sweden

Received: May 9, 2013; Accepted: October 5, 2013; Published: December 12, 2013

Copyright: © 2013 Klein et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Kristin Klein receives funding from the Clinical Investigators program at the University of Alberta. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist

Introduction

The identification of patients who are most likely to benefit from orthotopic liver transplantation (OLT) is a significant challenge in transplantation medicine. Liver transplantation offers the only curative therapy for patients with end-stage liver disease (ESLD). However, the supply of donor livers remains inadequate to meet the demand, necessitating an effective policy for organ allocation. In order to minimize waitlist mortality, a Model for End-Stage Liver Disease (MELD) - based organ allocation was proposed. First adopted by the United States in February 2002, it has become one of the most widely used approaches to prioritizing liver transplant candidates in countries around the world. The MELD score was initially developed by Malinchoc et al [1] to predict mortality in patients undergoing transjugular intrahepatic portosystemic shunts, but has since been validated as predictor of short-term mortality in patients awaiting transplantation. It uses objective variables (creatinine, bilirubin and the international normalized ratio of prothrombin time (PTINR)) to quantify the severity of ESLD, enabling the prioritization of patients in need of liver transplantation by medical urgency. An ideal system would allocate organs to patients not only at the highest risk of dying without transplantation, but also with the highest likelihood of survival following transplantation.

In recent years, the possibility of using pre-transplant MELD to predict post-transplant survival has been explored in many opinion pieces and expert reviews[2]. However, it has yet to be assessed through a systematic review and critical appraisal of published studies that adheres to internationally accepted systematic review guidelines. The need for such a review is heightened by the lack and infeasibility of RCTs on this topic and the fact that considerable debate over the value of MELD in this context remains. Thus, the aim of this study was to assess the association and predictive value of pre-transplantation MELD score on post-transplantation patient survival through a comprehensive, protocol driven systematic review of studies published to date.

Methods

Identification of potentially relevant studies

To identify relevant studies published as of August 2011, a structured search strategy combining relevant controlled vocabulary terms such as Medical Subject Headings (MeSH) and additional non-indexed terms was first developed. Such terms included Model for End-Stage Liver Disease, MELD, liver transplantation, liver failure, and survival. The search strategy was applied to the following electronic bibliographic databases: PubMed (MEDLINE and non-MEDLINE), the Cochrane Library, EMBASE, and Web of Science; and limited to full text, English language studies of adult patients which were published within the past 10 years. For completeness, reference lists of relevant articles were scanned. Also, an internet search for unpublished studies was performed with the Google® search engine. Full search details are provided in Table A in File S1.

Selection of studies for inclusion in the review

Two researchers independently screened the titles and abstracts of citations identified through the literature search using predetermined inclusion criteria (Table 1). The initial search strategy identified studies published in the last ten years, whereas only studies published since 2005 were included in the review.

Parameter Inclusion Criteria Exclusion Criteria
General Full-text articles published in the English language since 2005 Abstracts
Participants Adults patients with liver failure Patient populations not representing the general liver transplant population (ex: patients with HCC or HCV only)
Intervention Patient’s first orthotopic, whole liver, deceased-donor transplant Multi-organ transplants, non-standard donor or living donor transplants, split liver transplants, sequential transplants
Comparator Pre-operative Model for end-stage liver disease score Delta-Meld, MELD-Na, post-operative MELD score
Outcome Post-transplantation patient survival Survival rate not reported by MELD score
Study design Cohort, cross sectional, RCT, quasi-RCT, or controlled studies Case study or series, commentaries, and opinion pieces without primary data

Table 1. Inclusion/exclusion criteria for review.

Since the purpose of this study was to assess the predictive ability of MELD in the general transplant patient population, studies focussing on specific subgroups of patients were excluded, along with those involving only unique transplant conditions, such as multi-organ transplants, split livers, and non-standard donors. However, studies that considered these conditions within the context of the broader transplantation population were included in the review. Corresponding papers of citations deemed potentially relevant were then retrieved for full review. The level of consensus among reviewers was assessed using the Kappa Statistic. A score of 0.98 was achieved, indicating excellent agreement. Discrepancies among reviewers were resolved through discussion without the need for third party adjudication.

Extraction of data from included studies

Information from included studies was systematically extracted using a pre-tested data abstraction form. The abstraction form contained elements related to study design, patient population, comparators, outcomes measured, and findings. All studies were reviewed by the primary author, with a second reviewer extracting information on 50% of the studies. Reviewers subsequently met to compare results. No discrepancies were found. Therefore, a second, independent review of the remaining studies was deemed unnecessary.

Critical appraisal of included studies

Studies were appraised using the Oxford Center for Evidence-based Medicine Levels and Grades of Recommendation[3].

Data analysis and synthesis of results

Extracted data were tabulated to facilitate a comparison of findings across studies. A meta-analysis of pre-transplant MELD on post-transplant survival using a random effects model was also planned (see Results section). Prior to presenting pooled or summary estimates, clinical heterogeneity and statistical heterogeneity using the I2 statistic were assessed.

Results

Results of the literature search are presented in the PRISMA diagram (Figure 1). The search yielded 3058 discrete citations. Forty-eight full-text articles were retrieved for full consideration, of which 37 met the inclusion/exclusion criteria of the review. Among excluded studies, 6 involved inappropriate comparators or outcomes, 4 did not present primary data, and 1 contained data already captured in an included study. The list of excluded studies, along with reasons for exclusion, is presented in Table B in File S1.

journal.pone.0080661.g001

Figure 1. Literature search results and study selection for clinical review.

Description of included studies

The 37 studies comprised both prospective and retrospective case series, and collectively included a total of 53,691 patients. In most, the main objective was not to assess the relationship between MELD and post-transplant survival. Instead, studies examined a broad range of pre-transplant factors that may or may not influence survival through exploratory analyses. Studies originated from several countries, including: Belgium (2), New Zealand (1), the United Kingdom (3), Brazil (6), Spain (5), the United States (7), Singapore (1), Turkey (1), China (1), Korea (1), Switzerland (1), Poland (1), Italy (3), Canada (1), and Germany (3). The majority were single centered. Sample sizes ranged from 46 to 21,673 patients (mean = 1451, median = 222), most of whom were male. None used a power calculation to determine sample size. Sampling methods comprised consecutive patients who met inclusion/exclusion criteria, which differed considerably across studies. Therefore, patients comprising the “general transplant population” may have varied. The point at which MELD was measured in patients was inconsistent across studies, with some using time of placement on the transplant list and others using time of transplant. In most of the studies, the relationship between MELD and survival was examined through stratified analyses of survival across sub-groups defined by MELD score, where MELD cut-off points for sub-groups were determined post-hoc. Further, the majority(25) measured the association between MELD and survival based on univariate analyses alone, and, therefore, did not control for potential confounders. Eleven of the studies assessed the predictive ability of the MELD score on post-transplantation survival using a receiver operating characteristic (ROC) curve and the c-statistic. In 4 of the studies, there was partial overlap of patient populations since they included data from the Transplant Scientific Registry (Cywinski et al [4], Freeman et al [5], Rana et al [6] and Yoo & Thuluvath [7]). All of these studies were kept in the review as each used different MELD categories and follow-up times in their analysis. A detailed summary of each study is presented in Table C in File S1.

As mentioned above, the majority of studies grouped patients by MELD. Specifically, MELD, which represents a continuous variable, was converted to a categorical variable for the analyses. The cut-off points for such categories varied widely across studies and were typically determined post-hoc. (Refer to relevant outcome measures in Table C in File S1). Effect measures also differed, ranging from proportions to hazards ratios, odds ratios, and relative risks, and follow-up time periods were inconsistent. Lastly, characteristics of the “general transplant population” varied. Therefore, given such clinical heterogeneity across studies, a meta-analysis was deemed inappropriate, and a statistical assessment of heterogeneity was not performed.

Quality of included studies

Based on the Oxford Center for Evidence-based Medicine Levels of Evidence, the quality of all of the included studies was level IV. The studies, which involved a comparison of pre-transplant MELD scores with post-transplant survival, were all case series and predominantly retrospective in design. All studies recruited consecutive patients over a specified time period, thereby reducing the risk of selection bias.

Association between Pre-Transplant MELD Score and Post-Transplantation Survival

Of the 37 studies, 15 found no association between pre-transplant MELD score and post-transplant patient survival, while 22 reported poorer survival with higher MELD. A detailed description of the results of each study is presented in Table C in File S1. Based on qualitative analyses, there were no clear differences in studies with statistically significant findings compared to those with no statistically significant findings. In both groups, sample sizes varied, as did follow-up times. However, findings from the two largest studies (N >15,000) both suggested that survival decreased with increasing MELD. One observed this relationship only when patients with MELD scores under 9 were compared to those with scores of 30 or greater, while the other had treated MELD as a continuous variable. At the same time, of the 7 other studies that analysed MELD as a continuous variable, all but one found no statistically significant association between MELD and survival. In most of the studies, information presented on patient characteristics was limited. Therefore, it was not possible to identify any differences in patient populations that could explain inconsistencies in the findings.

Predictive ability of MELD score for post-transplantation survival

Eleven studies presented a receiver operating characteristic (ROC) curve to determine the predictive ability of pre-transplant MELD score to determine post-transplantation survival. The area under the curve is used to produce a concordance value called the c-statistic. A c-statistic of 0.50 indicates no predictive ability, and is expected if the results are due to chance alone. In contrast, a c-statistic of 1 represents perfect discrimination. Values under 0.7 suggest poor predictive power, while those greater than 0.70 indicate a useful test, and those higher than 0.80 imply excellent predictive accuracy[2]. Among the 11 studies, 10 reported c-statistics less than <0.7, indicating that MELD poorly predicted post-transplant survival. This included the largest study contributing to the review[6]. In 1 study, the c-statistic decreased over time, from 0.711 for 3-month post-transplant survival to 0.679 for 12-month survival[8]. In the single study with a high c-statistic[9], there was no clear difference in sample size, follow-up time, or patient population when compared to the studies with lower values.

Discussion

This review assessed the association and predictive ability of pre-transplantation MELD score on post-transplantation survival in adults with end-stage liver disease. It highlighted discrepancies in findings across studies. Such discrepancies may be related to the nature of the studies, The vast majority were retrospective case series that relied upon exploratory stratified analyses of data to detect a relationship between MELD and post-transplant survival. As such, analytical techniques, rather than study design, were used to control for confounding. In addition, most of the studies were single centered, with each site having its own process for prioritizing patients for transplant. Therefore, patients constituting the general transplant population may have varied across studies. Thus, while using pre-transplant MELD to predict post-transplant survival in transplant candidates may be attractive, there is little evidence to support it. Prospective studies designed specifically to examine this relationship are needed. MELD score does appear to have a greater impact on mortality when observed in combination with other known risk factors for post-transplant mortality, including sub-optimal livers, low graft-to-body ratio and presence of Hepatitis C. Further research in the area of particular patient subgroups (such as those with hepatitis C) may show a stronger association between MELD and post-transplant outcome.

Based on the studies conducted to date, which collectively represent a low level of evidence, MELD could be correlated with survival, but appears to have limited predictive ability. The vast majority of studies presenting concordance statistics found that pre-transplant MELD score offered minimal discriminating power for post-transplantation survival. However, the c-statistic may be of limited value in determining the predictive ability[10]. This is because the c-statistic is intended for diagnostic models, rather than prognostic models. The two types differ in that prognostic models add the element of time. Specifically, diagnostic models are designed to determine the current state of the patient and accurately identify an existing disease state. In contrast, prognostic models are designed to estimate the probability of a future state where the outcome is not yet known and subject to chance.

This review is limited by heterogeneity in key parameters of studies used to date, which precluded performance of a meta-analysis. Studies reported different comparators (in terms of MELD categories) and applied time-points for outcomes. Studies comparing standardized MELD categories would be beneficial in determining whether or not there is, in fact, a threshold level at which liver transplantation does not offer sufficient survival to warrant the use of scarce donor livers. A more accurate assessment of post-transplant survival would also need to look at other factors, such as quality of life. Research examining the combinations of patient factors using more appropriate statistical techniques may also be valuable in improving the predictive ability of pre-transplant elements on post-transplant outcome.

Conclusions

This study provides a comprehensive review of recent articles examining the relationship between pre-operative MELDS score and post-transplantation survival. Based on the results of studies conducted to date, it appears that the use of MELD does not serve as a reliable predictor of post-transplantation survival. This may be a reflection of a reliance on less than ideal analytical measures. However, the use of pre-transplant characteristics may always fall short of ensuring optimal organ allocation due to variability in immeasurable patient factors and the complexity of perioperative and postoperative conditions.

Supporting Information

Table A in File S1. Literature Search. Table B in File S1. Excluded Studies. Table C in File S1. Description of Included Studies [Download File S1, Checklist S1]

Acknowledgments

The authors would like to thank Leigh-Ann Topfer for assistance with the literature search, Mohamed El Shayeb for assistance with manuscript selection, and Andrea Dunn for assistance with data extraction.

Author Contributions

Conceived and designed the experiments: KK TS DM. Performed the experiments: KK TS. Analyzed the data: KK TS. Contributed reagents/materials/analysis tools: N/A. Wrote the manuscript: KK TS.

References

Source

December 8, 2013

Liver Stiffness Is Associated With Risk of Decompensation, Liver Cancer, and Death in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis

Clin Gastroenterol Hepatol. 2013 Dec;11(12):1573-1584.e2. doi: 10.1016/j.cgh.2013.07.034. Epub 2013 Aug 15.

Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, Kamath PS, Talwalkar JA.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: singh.siddharth2@mayo.edu.

Abstract

BACKGROUND & AIMS: Liver stiffness measurement (LSM), using elastography, can independently predict outcomes of patients with chronic liver diseases (CLDs). However, there is much variation in reporting and consistency of findings. We performed a systematic review and meta-analysis to evaluate the association between LSM and outcomes of patients with CLDs.

METHODS: We performed a systematic review of the literature, through February 2013, for studies that followed up patients with CLDs prospectively for at least 6 months and reported the association between baseline LSM and subsequent development of decompensated cirrhosis or hepatocellular carcinoma (HCC), as well as mortality. Summary relative risk (RR) estimates per unit of LSM and 95% confidence intervals (CIs) were estimated using the random effects model.

RESULTS: Our final analysis included 17 studies, reporting on 7058 patients with CLDs. Baseline LSM was associated significantly with risk of hepatic decompensation (6 studies; RR, 1.07; 95% CI, 1.03-1.11), HCC (9 studies; RR, 1.11; 95% CI, 1.05-1.18), death (5 studies; RR, 1.22; 95% CI, 1.05-1.43), or a composite of these outcomes (7 studies; RR, 1.32; 95% CI, 1.16-1.51). We observed considerable heterogeneity among studies-primarily in the magnitude of effect, rather than the direction of effect. This heterogeneity could not be explained by variations in study locations, etiologies and stages of CLD, techniques to measure liver stiffness, adjustment for covariates, or method of imputing relationship in the meta-analysis.

CONCLUSIONS: Based on a meta-analysis of cohort studies, the degree of liver stiffness is associated with risk of decompensated cirrhosis, HCC, and death in patients with CLDs. LSM therefore might be used in risk stratification.

Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

KEYWORDS: CI, CLD, Cancer, Cirrhosis, Elastography, HCC, HCV, HR, HVPG, LSM, LT, MELD, MRE, Outcomes, Prognosis, RR, TE, chronic liver disease, confidence interval, hazard ratio, hepatic venous pressure gradient, hepatitis C virus, hepatocellular carcinoma, liver stiffness measurement, liver transplantation, magnetic resonance elastography, model for end-stage liver disease, relative risk, transient elastography

PMID: 23954643 [PubMed - in process]

Source

November 11, 2013

Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine

Tsang Lau, Jawad Ahmad
Division of Liver Diseases, Mount Sinai School of Medicine, New York, USA

Abstract: The Model for End-Stage Liver Disease (MELD) score incorporates serum bilirubin, creatinine, and the international normalized ratio (INR) into a formula that provides a continuous variable that is a very accurate predictor of 90-day mortality in patients with cirrhosis. It is currently utilized in the United States to prioritize deceased donor organ allocation for patients listed for liver transplantation. The MELD score is superior to other prognostic models in patients with end-stage liver disease, such as the Child–Turcotte–Pugh score, since it uses only objective criteria, and its implementation in 2002 led to a sharp reduction in the number of people waiting for liver transplant and reduced mortality on the waiting list without affecting posttransplant survival. Although mainly adopted for use in patients waiting for liver transplant, the MELD score has also proved to be an effective predictor of outcome in other situations, such as patients with cirrhosis going for surgery and patients with fulminant hepatic failure or alcoholic hepatitis. Several variations of the original MELD score, involving the addition of serum sodium or looking at the change in MELD over time, have been examined, and these may slightly improve its accuracy. The MELD score does have limitations in situations where the INR or creatinine may be elevated due to reasons other than liver disease, and its implementation for organ allocation purposes does not take into consideration several conditions that benefit from liver transplantation. The application of the MELD score in prioritizing patients for liver transplantation has been successful, but further studies and legislation are required to ensure a fair and equitable system.

Keywords: MELD score, liver transplantation

Cirrhosis is typically a progressive condition characterized by marked fibrosis and nodule formation in the liver due to a number of causes. It is usually irreversible and led to over 30,000 deaths in the United States in 2009, making it the 12th leading cause of mortality.1 Cirrhotic patients can have well-compensated disease with little or no symptoms or present with decompensated disease, including ascites, encephalopathy, or gastrointestinal bleeding, due to portal hypertension. These latter patients are candidates for liver transplantation (LT).2

There are currently 15,000 patients awaiting LT in the United States, and only 6000–6500 transplants are performed annually; meanwhile, there is a 10% rate of death on the waiting list.3 Historically, allocation of deceased donor (DD) organs for LT was based primarily upon the amount of time a patient spent on the waiting list and subjective measures of disease severity. In 1998, the US Department of Health and Human Services issued its “Final Rule,” calling on the transplant community to establish a set of objective criteria in prioritizing patients for transplant that were most at need.4 Subsequently, the Model for End-Stage Liver Disease (MELD) was developed and adapted as a prognostic tool in advanced liver disease and is now used by UNOS to prioritize DD organ allocation for patients listed for LT.5 The validity of the MELD score has since been shown in a variety of clinical scenarios to prognosticate the outcome in patients with advanced liver disease.

Continue here to read complete article (PDF) …..

November 8, 2013

Liver Meeting speaker: HCC exceptions contributing to MELD inflation, transplant inequity

Provided by Healio

November 3, 2013

WASHINGTON – Changes should be considered to the Model for End-stage Liver Disease scoring system to improve equity on the transplant waiting list,Patrick G. Northup, MD, of the division of gastroenterology and hepatology in the department of medicine at the University of Virginia, said at The Liver Meeting.

“Regulatory authorities and the transplant community should decide whether transplant should be preferential to HCC [hepatocellular carcinoma], or whether it should treat all diseases equally,” he said. “The current system is self-fulfilling ... HCC exceptions have better wait-list survival and better short-term outcome.”

Researchers analyzed all adult, initial transplant candidates listed for liver transplantation from 2005 to 2012, other than status one candidates, to determine whether HCC exceptions are related to the increase in MELD scores on the U.S. liver transplant waiting list.

The study found those candidates with HCC exceptions experienced significantly fewer mean days on the waiting list in comparison to those without exceptions, largely due to the lower lab-based MELD score. Those with HCC waited a mean of 257 days, compared with 420 days for non-HCC patients (P<.0001)

Similar results were seen in HCC vs. non-HCC transplantation rates (65.4% to 44.2%, P<.0001) and waiting-list death rate (13.5% to 22.3%).

Furthermore, the number of exceptions granted for HCC patients was found to be directly and independently associated with the average MELD score of all candidates at the time of removal (P<.00001), Northup said.

Overall, MELD scores are increasing about 2% per year, he said, noting a strong association between those increasing scores and the upgrades transplant candidates with HCC exceptions are given.

“We should ask ourselves: ‘Does the current system truly give access to the sickest first?’ ” Northup said, before concluding that “we should use extreme caution when considering adding new exceptions to the MELD system … as upgrades to the current MELD system have unintended consequences.”

Disclosure: Northup receives grant and research support from Hemosonics, Bristol Myers Squibb.

For more information:

Northup P #1: MELD Inflation: The Current Hepatocellular Carcinoma Exception Policy is Primarily Responsible for Steadily Increasing MELD Scores at the Time of Liver Transplant in All Regions of the U.S. Presented at: The Liver Meeting 2013; Nov. 1-5, Washington.

Source

November 4, 2013

More HCV Patients on Transplant Lists

Meeting Coverage

Published: Nov 4, 2013

By Michael Smith, North American Correspondent, MedPage Today

Action Points

Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

WASHINGTON -- An increasing number of patients on liver transplant waiting lists have hepatitis C (HCV), researchers found.

But the increase is almost entirely due to an increasing number of HCV patients wait-listed for transplant because of hepatocellular cancer (HCC), according to Jennifer Flemming, MD, of Queen's University in Kingston, Ont.

The proportion of wait-listed patients whose viral infection led to end-stage liver disease (ESLD) remained roughly stable over an 8-year period ending in 2010, Flemming reported at the annual meeting of the American Association for the Study of Liver Diseases.

The trend is likely to continue, Flemming concluded, and could "further strain our already limited donor pool."

An important element in the changes over time is the Model for End-stage Liver Disease (MELD), which is used by the United Network of Organ Sharing to allocate organs, Flemming said. The model is based mainly on the degree of hepatic decompensation but has been modified to give patients with liver cancer a higher priority than they would otherwise get.

Flemming and colleagues looked at data from the Scientific Registry of Transplant Recipients for January 2003 through December 2010 to estimate longitudinal trends in liver transplantation secondary to HCV.

The issue is important, because the prevalence of HCV-related cirrhosis is rising and is expected to peak in 2020 at about a million Americans, she said. At the same time, the prevalence of ESLD and HCC is also expected to peak in 2020 at 150,000 and 14,000 patients, respectively.

Over the 8 years of the study, Flemming said, 20,325 HCV patients were wait-listed for transplant, including 12,724 with ESLD and 7,061 with HCC.

The yearly totals rose steadily from 2,074 in 2003 to 3,053 in 2020. But the number of those with ESLD only rose from 1,451 to 1,674, while the numbers with HCC more than doubled, from 623 in 2003 to 1,379 in 2010.

Compared with the general population, she said, the overall rate rose from 6.9 to 10.2 wait-listed patients per 100,000 and the rate for those with ESLD went from 4.8 to 5.6 per 100,000.

On the other hand, the rate for patients with HCC rose from 2.1 to 4.6 per 100,000.

In other words, Flemming said, the overall rise is "all due to the increased listing of patients with hepatocellular carcinoma."

Overall, the yearly increase was 4.7% and was statistically significant at P<0.001, while the yearly increase for ESLD was 0.7% and did not reach significance.

The yearly increase for HCC was 11.8% and was again significant at P<0.001.

Physicians involved with liver transplantation have noticed they are transplanting more HCV patients with cancer, commented Kenneth Chavin, MD, PhD, of the Medical University of South Carolina in Charleston, who was not part of the study but who moderated the session at which it was presented.

"But this is a very well-done study that confirms what we're seeing," Chavin told MedPage Today.

He added that there is active consideration to changing the rules for transplant to redress the imbalance. And, he said, the advent of new, more effective treatments for HCV might also change the pattern.

Source

September 7, 2013

MELD score, allocation, and distribution in the United States

Clinical Liver Disease

Volume 2, Issue 4, pages 148–151, August 2013

Review

Joel P. Wedd1, Ann M. Harper2, Scott W. Biggins1,*

Article first published online: 19 AUG 2013

DOI: 10.1002/cld.233

Copyright © 2012 the American Association for the Study of Liver Diseases

Abstract

Watch a video presentation of this article

Watch the interview with the author

Answer questions and earn CME

There is a critical mismatch in liver transplant supply and demand (Fig. 1). In order to manage this scarce resource, the transplant community in the United States has used the Model for End-Stage Liver Disease (MELD) score as the backbone of its adult liver transplantation allocation and distribution system since February 2002. The MELD score was implemented in response to the Organ Procurement and Transplantation Network (OPTN) Final Rule, a Department of Health and Human Services mandate to de-emphasize waiting time and focus on disease severity and waiting list mortality risk.1 The MELD score uses objective parameters to estimate the short-term risk of death in patients who are on the transplant list. Compared with the previous system, which used the Child-Turcotte-Pugh score2 and patient location (i.e., outpatient, hospital floor, or intensive care unit) to prioritize liver allocation, the MELD-based system was thought to be far more difficult to manipulate and less dependent upon waiting times for organ allocation. There was immediate evidence of a positive impact of the MELD score implementation, with fewer listings of low MELD patients and shorter waiting time on the liver transplant list in the first year of the post-MELD era.3 Despite the listing of sicker patients, however, there was no reduction in posttransplantation patient or graft survival.4

nfig001

Figure 1. Discrepancy between candidates on the liver transplant waiting list and liver transplants.

The MELD equation uses the international normalized ratio, creatinine, and total bilirubin to determine a score from 6 to 40 (capped by United Network for Organ Sharing) and predicts 3-month mortality risk5 (Fig. 2):

tex2gif-ueqn-1

where INR is the international normalized ratio.

nfig002

Figure 2. Three-month waiting list mortality risk by MELD score.

The objectivity and ease of laboratory measurement of its variables make the MELD score an attractive organ allocation tool. After listing, every patient is placed on the list based upon their calculated or exception MELD score, which is periodically updated while awaiting transplantation. Patients whose calculated MELD score is not reflective of their risk of death or who drop out from the transplant list can be considered for exception points. Some disease states (hepatocellular carcinoma, hepatopulmonary syndrome, primary hyperoxaluria, familial amyloid polyneuropathy, cystic fibrosis with progressive pulmonary deterioration, portopulmonary syndrome, and cholangiocarcinoma receiving an approved chemoradiation protocol) can receive standardized MELD exception points provided they fit within predetermined criteria. Other considerations (e.g., hyponatremia and frequent cholangitis in primary sclerosing cholangitis) do not qualify for standard MELD exception points but are reviewed by each region's review board. The justifications for MELD exception points for many of these conditions were reviewed by a national concensus conference (MELD Exception Study Group and Conference, MESSAGE), which agreed on guidelines that are not used by all regions or all regional reviewers.6

Liver Transplantation Allocation and Distribution

Prioritization on the transplant waiting list is ordered by increased risk of death as determined by the MELD score (either calculated or exception MELD score, whichever is highest) with the exception of status 1a patients (acute liver failure, primary graft dysfunction, or hepatic artery thrombosis within 1 week of transplantation) and status 1b patients (children with chronic liver disease and life-threatening complications), who are prioritized first. For more information on the current allocation system, please see the Organ Procurement and Transplantation Network (OPTN) website (policy 3.6).7 The United States liver organ distribution is organized into 58 federally approved Donation Service Areas, each served by an Organ Procurement Organization (Fig. 3). With the exception of status 1A and 1B candidates, local candidates are prioritized over regional and national candidates.8 The priority MELD score cutoff for nonlocal candidates receiving an adult deceased donor liver offer preferentially over a local candidate is under continual revision to provide the most equitable sharing between regions that have inherently different demographics and degrees of illness. Currently, the “Share 15 Regional” policy establishes that cutoff at a MELD score of 15. If there are no local candidates above a MELD score of 15, the liver is offered regionally to candidates with scores of 15 or higher. The MELD score of 15 was chosen because of a seminal study showing that the balance between the risk of death on the transplant list versus risk of death with transplant surgery reverses around a MELD score of 15, with scores lower than 15 favoring staying on the transplant list and higher scores favoring accepting the risk of the surgery.9

nfig003

Figure 3. Organ Procurement Organization (OPO) donation service area map.

Despite its improvement over previous allocation systems, the MELD score's weaknesses are widely recognized and reported. All of the MELD variables are subject to one or more of the following biases: laboratory variation,10, 11inaccuracy due to surrogate measurement and differential effects between men and women,12 and lack of specificity to liver disease.13 These biases may cause changes in an individual patient's MELD score that are not reflective of the patient's liver disease and therefore inappropriately change that patient's MELD-determined transplant priority. Despite these inherent weaknesses, the MELD score has created an evidence-based gold standard to assess risk equivalency in end-stage liver disease.

Abbreviations

MELD Model for End-Stage Liver Disease

OPTN Organ Procurement and Transplantation Network.

Recent Changes and Future Directions

Conversations within the transplant community are currently taking place to determine the next steps in MELD score, allocation, and distribution. The goal is to improve liver transplant equitability in the United States without sacrificing the objectivity and accessibility of the MELD score. The stated strategy involves small, incremental changes over time. In terms of allocation, the leading consideration is the MELDNa score—an equation similar to the MELD score that incorporates sodium and has shown better predictive ability than the MELD score, especially in low MELD scores.14, 15 A proposal to incorporate the MELDNa score into the United States allocation system was submitted for public comment in Spring 2013. Efforts to refit the MELD score variables with new coefficients in cohorts larger than those of the original MELD studies have resulted in higher predictive ability, both with and without sodium in the score,16, 17 but this is currently not under consideration for implementation.

There have also been several efforts to change the distribution system to reduce geographic disparities. Two of these efforts, Share 15 National and Share 35 Regional were implemented in June 2013. In Share 15 National, adult deceased donor livers are offered nationally to status 1 patients and patients with MELD 15 or higher before local/regional/national patients with MELD scores less than 15 (Table 1). In Share 35 Regional, regional patients with MELD scores above 35 receive offers before local patients below a MELD score of 35. At each MELD score of 35 to 40, local candidates retain priority over regional patients. The threshold of a MELD score of 35 was chosen because of modeling studies suggesting equivalent wait list outcomes of status 1 patients and patients with a MELD score above 35.18

Table 1. United States Adult Deceased Donor Liver Distribution Policy

Share 15 Share 15 National Share 15 National with Share 35 Regional
  1. Offers for livers are prioritized from top to bottom and are only offered to a lower priority candidate if there are no accepting candidates in previous rows. Share 15 was the distribution strategy until recently. Share 15 National and Share 35 Regional were implemented in Spring 2013.

Local status 1A Local status 1A Local status 1A
Regional status 1A Regional status 1A Regional status 1A
Regional status 1B Regional status 1B Regional status 1B
Local MELD score ≥15 Local MELD score ≥15 Candidates with MELD/PELD scores ≥35 in descending order of MELD score, with local candidates ranked above regional candidates at each level of MELD score
Regional MELD score ≥15 Regional MELD score ≥15 Local MELD score ≥15
Local MELD score <15 National status 1A Regional MELD score ≥15
Regional MELD score <15 National status 1B National status 1A
National status 1A National MELD score ≥15 National status 1B
National status 1B Local MELD score <15 National MELD score ≥15
National MELD Regional MELD score <15 Local MELD score <15
  National MELD score <15 Regional MELD score <15
    National MELD score <15

Conclusion

The MELD score drastically changed the liver transplant allocation system in the United States. It was a positive adjustment in the history of liver transplantation, though the system still has significant shortcomings in interregional equitability. Research and debate is ongoing in the liver transplant community regarding what changes to make in the future to improve equitable use of this scarce resource.

References

Source

August 21, 2013

Hepatitis C virus: Antiviral therapy in wait-listed patients

Clinical Liver Disease

Volume 2, Issue 4, pages 173–176, August 2013

Review

Asmeen Bhatt M.D., Ph.D.*, Gregory T. Everson M.D.

Article first published online: 19 AUG 2013

DOI: 10.1002/cld.225

Copyright © 2012 the American Association for the Study of Liver Diseases

Abstract

Watch a video presentation of this article

Watch the interview with the author

Answer questions and earn CME

Recurrent infection with hepatitis C virus (HCV) after liver transplantation (LT) is universal in patients who are viremic at the time of transplantation. Recurrent HCV is associated with reduced graft survival and increased patient mortality.1, 2 Current antiviral treatments for established posttransplant recurrence are characterized by low rates of virological clearance, poor tolerability, cytopenias, infections, drug interactions with immunosuppressants, and a risk of allograft rejection. In addition, allografts are often significantly damaged by HCV by the time of the initiation of antiviral treatment.3 Preventing the recurrence of HCV infection is desirable.

Pretransplant antiviral therapy for wait-listed patients is one strategy for preventing allograft reinfection by HCV. In some cases, achieving a sustained virological response (SVR) might stabilize or reverse the liver disease and potentially prevent the need for LT. However, for most wait-listed patients, the primary goal is rendering the blood free of HCV at the time of transplantation to achieve posttransplant viral clearance, which is defined as HCV RNA being undetectable 12 weeks or more after transplantation [posttransplant viral response (pTVR)]. Achieving pTVR eliminates the risk of recurrence and should preserve graft function, increase graft survival, and improve patient outcomes and survival.4, 5, 6, 7 Despite the potential benefits, the effectiveness of pretransplant treatment is dependent on the potency and tolerability of the antiviral regimen and the severity of the underlying liver disease.

Interferon-Based Treatment

Current treatment options are limited. The standard of care for HCV genotype 1 (GT1) is peginterferon (PEG)/ribavirin (RBV) plus either telaprevir or boceprevir (triple therapy).8, 9, 10, 11, 12 For non-1 genotypes, the standard of care is PEG/RBV alone.13, 14, 15 These treatments are less effective in patients with cirrhosis because of reduced virological responses and poor tolerability.

Patients with HCV on the waiting list exhibit a wide range of disease severity, which affects selection for treatment. Interferon-related side effects, adverse reactions, and serious adverse events occur with greater frequency and severity in patients with decompensated cirrhosis. Patients with high Model for End-Stage Liver Disease (MELD) scores or clinical complications such as ascites, variceal hemorrhage, and encephalopathy are poor candidates because they are at increased risk for serious infections, hepatic decompensation, and even death. Thus, interferon-based treatment is limited to patients with MELD scores < 18 and lesser hepatic impairment, such as potential recipients of living donor grafts and potential recipients of deceased donor grafts with MELD upgrades for hepatocellular carcinoma.

The Low Accelerating Dose Regimen-Adult-to-Adult Living Donor Liver Transplantation Study (LADR-A2ALL) was a randomized controlled trial of PEG/RBV treatment.16 Candidates included HCV patients with either potential living donors or MELD upgrades for hepatocellular carcinoma. Among the treated GT1/genotype 4 (GT4)/genotype 6 (GT6) patients, 23 of 30 received a transplant, and 22% of these patients achieved pTVR. Among the treated genotype 2 (GT2)/genotype 3 (GT3) patients, 21 of 29 received a transplant, and 29% of these patients achieved pTVR. The likelihood of achieving pTVR was related to the duration of treatment: 50% of the patients who received the treatment for >16 weeks achieved pTVR (P = 0.01; Fig. 1). The overall pTVR rate reported in this study (25%) was similar to the rates reported by Everson et al.17 (26%), Forns et al.18 (23%), and Carrión et al.19 (23%). In all of these studies, some treated patients experienced serious, even life-threatening adverse events (mainly infections). Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis is recommended. Patients with cirrhosis frequently have baseline cytopenias that worsen during treatment. In LADR-A2ALL, 75% of the treated patients required an erythropoietin analogue or granulocyte colony-stimulating factor, alone or in combination.16 Eltrombopag can raise platelet counts and potentially improve the chances for SVR, but it carries a risk for portal vein thrombosis and hepatic decompensation.20

nfig001

Figure 1. Results of pretransplant treatment with the low accelerating dose regimen in LADR-A2ALL.16 The likelihood of pTVR was related to the duration of treatment: the pTVR rate was 50% for patients receiving greater than 16 weeks of PEG/RBV. At LTx refers to the HCV RNA status at the time of LT; pTVR indicates undetectable HCV RNA 12 weeks or more after transplantation.

Patients infected with HCV GT1 currently have the option to be treated with triple therapy. The A New Direction in HCV Care: A Study of Treatment-Naive Hepatitis C Patients with Telaprevir (ADVANCE),9 Illustrating the Effects of Combination Therapy with Telaprevir (ILLUMINATE),11 and Serine Protease Inhibitor Therapy-2 (SPRINT-2) studies10 showed that patients with cirrhosis have much higher rates of SVR when they are treated with triple therapy versus PEG/RBV. SVR with triple therapy is also predicted by the responsiveness to interferon. Patients who have interleukin-28b polymorphism CC (versus CT or TT), a greater than 1 log10 drop in HCV RNA during the lead-in with PEG/RBV, or a relapse response to prior PEG/RBV are more likely to achieve SVR when they are treated with triple therapy.8, 9, 10, 11, 12

There is limited information regarding the use of triple therapy in wait-listed patients. Verna et al.21 presented results for 28 HCV GT1 patients awaiting LT. Nine (32%) discontinued treatment because of adverse events, a null response, relapse, hepatic decompensation, or death. Rates for achieving undetectable HCV RNA were 50%, 71%, and 80% at weeks 4, 8, and 12, respectively. Eight patients (28%) underwent LT, and six of them had undetectable HCV RNA after transplantation (pTVR rate = 75%). One patient with pTVR received only 3 weeks of triple therapy. Among the transplant patients, 75% were treatment-experienced, and 88% had hepatocellular carcinoma. There were two deaths: one before transplantation (due to an unknown cause) and one after transplantation (due to sepsis).

This early experience suggests that pretransplant treatment using triple therapy may be more effective than PEG/RBV alone in achieving pTVR in patients with an HCV GT1 infection. However, the treatment is complicated by serious side effects, adverse events, and potentially life-threatening complications. Anemia is a major problem requiring RBV dose reduction, the use of erythropoietin analogues, and blood transfusions.

Abbreviations

1st first-generation drug, 2nd later generation drug, 5aI inhibitor of nonstructural 5A protein, DAA direct-acting antiviral, GT1 genotype 1, GT2 genotype 2, GT3 genotype 3, GT4 genotype 4, GT5 genotype 5, GT6 genotype 6 ,HCV hepatitis C virus, LADR-A2ALL Low Accelerating Dose Regimen-Adult-to-Adult Living Donor Liver Transplantation Study, LT liver transplantation, MELD Model for End-Stage Liver Disease, NI nucleos(t)ide-based inhibitor of nonstructural 5B polymerase, PEG peginterferon, PI inhibitor of nonstructural 3/4A protease, pTVR posttransplant viral response, RBV ribavirin, SOF sofosbuvir, SVR sustained virological response

Emerging Drugs and Interferon-Free Treatment

The next wave of antiviral drugs for HCV may include sofosbuvir (SOF; nonstructural 5b polymerase inhibitor), simeprevir (nonstructural 3/4a protease inhibitor), faldaprevir (nonstructural 3/4a protease inhibitor), and daclatasvir (nonstructural 5a protein inhibitor). These drugs have greater potency, a lower potential for drug-drug interactions, once daily dosing, a shorter duration of therapy, and fewer side effects. The increased tolerability should expand the pool of pretransplant patients who could be candidates for treatment22 (Table 1).

Table 1. Speculations Regarding Future Drug Regimens for Pretransplant Treatment, Timelines, and Potential or Expected SVR or pTVR Rates, Treatment Durations, and Severity of Side Effects

Genotype Year Treatment Options SVR or pTVR Rate (%) Optimum Duration of Treatment (%) Severity of Side Effects
<8 Weeks 8-16 Weeks >16 Weeks
  1. This table was adapted with permission from Clinics in Liver Disease.22 Copyright 2013, Elsevier.

  2. Abbreviations: 1st, first-generation drug; 2nd, later generation drug; 5aI, inhibitor of nonstructural 5A protein; NI, nucleos(t)ide-based inhibitor of nonstructural 5B polymerase; PI, inhibitor of nonstructural 3/4A protease. + shows severity of side effects, where + is minimum and +++++ is maximum side effects.

GT2 or GT3 2013 PEG/RBV 29-50 100 ++++
≥2013 RBV-NI >65 20 80 +
GT1a or GT1b 2013 PEG/RBV 20-25 100  
2013 PEG/RBV + PI-1st 40 80 20 +++++
≥2013 PEG/RBV + PI-2nd 55 80 20 +++
≥2014 PEG/RBV-5aI 55 80 20 +++
≥2014 PEG/RBV-NI >60 100 ++
≥2014 RBV-NI >55 100 +
≥2014 Multi-DAA >60 20 80 ++
GT1b ≥2014 5aI + PI-2nd >60 20 80 +
GT1a >2014 PEG/RBV + 5aI + PI-2nd >60 20 80 ++

GT1 [and GT4, Genotype 5 (GT5), and GT6]

The initial use of SOF, simeprevir, faldaprevir, or daclatasvir in patients infected with HCV GT1, GT4, GT5, or GT6 is likely to be in combination with PEG/RBV. In a trial of treatment-naive patients, 17% of whom had cirrhosis, 12 weeks of SOF/PEG/RBV achieved an SVR rate of 92% in patients without cirrhosis and an SVR rate of 80% in patients with cirrhosis23 (Fig. 2). In studies of simeprevir/PEG/RBV, 85% to 93% of patients had a rapid virological response and qualified for a reduced treatment duration of 24 weeks. Overall, 79% to 81% of patients achieved SVR despite F3/F4 fibrosis in 22% to 31% of the cases (Medivir press releases, December 2012). Clearly, the new drugs offer advantages over both telaprevir and boceprevir: higher potency, ease of dosing, and fewer side effects. However, virological responses may be further impaired in sicker wait-listed patients who have more advanced liver disease.

nfig002

Figure 2. Impact of cirrhosis on SVR with SOF-based treatment.23, 27 Cirrhosis reduces the likelihood of achieving SVR during SOF treatment. This effect of cirrhosis is true whether patients are treatment-naive (GT1 and GT3); interferon-ineligible, intolerant, or unwilling (GT3); or treatment-experienced (GT2 and GT3). The negative impact of cirrhosis on SVR can be at least partially reversed by an extension of the duration of SOF/RBV treatment (GT2 and GT3). P stands for PEG/RBV, % SVR 12 stands for sustained viral response at 12 weeks post treatment. Weeks indicated in the X-axis are duration of total treatment.

Preliminary results with multi direct-acting antivirals (DAAs), interferon-free regimens in HCV GT1 patients without cirrhosis are very encouraging.24, 25, 26 SVR rates approach 100% with few, if any, side effects or adverse reactions. Promising combinations, with or without RBV, include SOF/ledipasvir, SOF/daclatasvir, SOF/simeprevir, daclatasvir/asunaprevir, daclatasvir/asunaprevir/BMS-791325, and ABT-450/r/ABT-333/ABT-267. We must emphasize that none of these regimens has been adequately tested in patients with cirrhosis (particularly decompensated cirrhosis) or in patients on the waiting list for LT.

GT2 and GT3

Three phase 3 trials have examined the efficacy of SOF/RBV in patients infected with HCV GT2 or GT323, 27 (Fig. 2). HCV RNA declines rapidly and is undetectable by week 4 in nearly all patients. Treatment failures are primarily due to relapse without evidence of viral resistance. The reported side effects have been those associated with RBV. Treatment-naive patients with HCV GT2 (even those with cirrhosis) achieved an SVR rate > 90% with 12 weeks of treatment. Treatment-experienced HCV GT2 patients with cirrhosis benefited from an extension of the treatment from 12 to 16 weeks (the SVR rate improved from 60% to 78%). Treatment-experienced HCV GT3 patients with cirrhosis demonstrated the greatest improvement in SVR when the treatment duration was increased from 12 to 16 weeks (the SVR rate increased from 19% to 61%).

This simple all-oral regimen would seem to be ideal as a pretransplant treatment for preventing recurrent infection of the allograft. However, the metabolic derangements and portosystemic shunting of cirrhosis could alter the pharmacokinetics and bioavailability of these drugs and impair efficacy. We anxiously await results from studies of interferon-free combinations of DAAs in cirrhosis and advanced liver disease.

In summary, the era of DAAs for HCV has expanded treatment options for the wait-listed patient. Rates of pTVR after pretransplant treatment have improved with current triple therapy, but the management of side effects and complications remains challenging. Future regimens incorporating interferon-free, multi-DAA treatments should improve the effectiveness and tolerability of pretransplant treatment.

References

Source